Abstract. The aim of the present study was to identify the disease-associated genes and their functions involved in the development of three types of glioma (astrocytoma, glioblastoma and oligodendroglioma) with DNA microarray technology, and to analyze their differences and correlations. First, the gene expression profile GSE4290 was downloaded from the Gene Expression Omnibus database, then the probe-level data were pre-processed and the differentially expressed genes (DEGs) were identified with limma package in R language. Gene functions of the selected DEGs were further analyzed with the Database for Annotation, Visualization and Integrated Discovery. After the co-expression network of DEGs was constructed by Cytoscape, the functional modules were mined and enrichment analysis was performed, and then the similarities and differences between any two types of glioma were compared. A total of 1151 genes between normal and astrocytoma tissues, 684 genes between normal and malignant glioma tissues, and 551 genes between normal and oligodendroglioma tissues were filtered as DEGs, respectively. By constructing co-expression networks of DEGs, a total of 77232, 455 and 987 interactions were involved in the differentially co-expressed networks of astrocytoma, oligodendroglioma and glioblastoma, respectively. The functions of DEGs were consistent with the modules in astrocytoma, glioblastoma and oligodendroglioma, which were mainly enriched in neuron signal transmission, immune responses and synthesis of organic acids, respectively. Model functions of astrocytoma and glioblastoma were similar (mainly related with immune response), while the model functions of oligodendroglioma differed markedly from that of the other two types. The identification of the associations among these three types of glioma has potential clinical utility for improving the diagnosis of different types of glioma in the future. In addition, these results have marked significance in studying the underlying mechanisms, distinguishing between normal and cancer tissues, and examining novel therapeutic strategies for patients with glioma.
Introduction
Glioma derived from glial cells is the most common type of primary intracerebral neoplasm, accounting for >40% of all primary brain tumors in humans (1) , and typically has a poor prognosis (2) . The classification of glioma varies depending on different standards. In the present study, the three most prevalent types of glioma that exhibit a high degree of malignancy were selected for in-depth analysis, astrocytoma, oligodendroglioma and glioblastoma. Astrocytoma has the highest morbidity; oligodendroglioma, which originates from the interstitial cells is more common than the neuronal tumor that originates from the parenchyma cells; while the medical history of glioblastoma is notably short (3) .
Glioma has been the subject of an increasing number of studies over the past two decades, that has resulted in considerable advances in the understanding of basic biology and pathogenesis (3, 4, 5) . This accumulative evidence is contributing to development of novel pharmacological strategies to target the key molecular pathways involved in gliomas and reduce the resulting mortality and morbidity by 2020 (6) . Despite aggressive treatment with surgery, radiation and chemotherapy, the average survival time for glioma patients remains only 14 months (7) . Therefore, more effective therapies are urgently required. Furthermore, due to the progressive nature of cancer, which involves multiple mutations, individual gene analysis may only provide limited insights into the cellular mechanisms underlying carcinogenesis (8) . Therefore, further investigation of the pathogenetic basis of glioma is imperative.
In recent years, with the continuous development of biotechnology and the innovation of novel high throughput technology, studies have begun to investigate the occurrence and development of diseases at the genome level, and gene chip technology is commonly used to detect genome-wide gene expression at the transcriptome level. Numerous studies have screened biomarkers associated with diseases by analyzing gene expression profiling (9,10), and have analyzed the pathogenesis of various complex diseases (11) by associating the gene expression level with biological networks, including protein interaction networks (12) , regulation and metabolic networks (13) and signal networks (14) . The present study aimed to identify the disease-associated genes and gene functions in three types of glioma (astrocytoma, glioblastoma and oligodendroglioma) based on DNA microarray gene expression profiling and to analyze their differences and correlations, which may provide novel avenues for more advanced investigation into the mechanisms underlying glioma. Improving the understanding of the molecular mechanisms of glioma may provide evidence that aids in the development of early diagnosis and treatment strategies for patients.
Materials and methods
Microarray data. Gene Expression Omnibus (GEO) (15) (http://www.ncbi.nlm.nih.gov/geo/) is currently the largest and most comprehensive public gene expression database. The gene expression data stored in GEO is mainly submitted from laboratories worldwide, including Affymetrix microarray data, expressed sequence tag sequence data, serial analysis of gene expression sequence data and second generation sequence data. Each set of the submitted expression profile data include information of platforms, sequences and samples. The gene expression profile GSE4290 (16) Data preprocessing. According to the corresponding correlation between the probe and gene from the GPL570 platform [HG-U133_Plus_2](Affymetrix Human Genome U 133 plus 2.0 Array; Affymetrix, Santa Clara, CA, USA) the probe numbers of the expression profile were converted into the corresponding gene symbols. One gene corresponds with multiple probes, thus each gene has more than one expression value. Therefore, the average value was calculated and selected as the only representative value. A total of 20308 genes were involved following processing. Background correction and quartile data normalization were performed by the robust multiarray average in R affy package (Affymetrix).
Differentially expressed genes (DEGs) analysis. The limma package (Affymetrix)(17) was used to identify the DEGs between the normal and three glioma tissues, respectively. The cut-off criterion was P<0.01. (20) . Therefore, the construction of a gene co-expression network facilitates the identification of gene collections with similar functions (21) . Gene co-expression networks were constructed in the following procedure. Firstly, the expression values of normal samples were removed from the expression profile data. Secondly, Pearson's correlation coefficient between two DEGs was calculated according to the formula below, and the pairs whose correlation was >0.7 were selected as the co-expressed gene pairs:
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Where r is the Pearson's correlation coefficient; n is the sample size; X -is the average of sample X; Y -is the average of sample Y; δ X is the standard deviation of sample X; and δ Y is the standard deviation of sample Y. Finally, clusterviz package in Cytoscape (22) was used to construct the co-expression network (1).
Function module mining and analysis. MCODE (23) was used to mine the function modules in the co-expression networks. The MCODE algorithm includes three steps: (i) The weight calculation of network vertex; (ii) the compound prediction; and (iii) the subsequent node filter or addition of the compound based on certain connection indicators. The network clustering coefficient Ci was selected as the node weight [Ci=2 * n/Ki * (Ki-1), where Ki represents the node number directly connected with the node i, and n represents the connected edge number of these nodes. The node with the largest weight was taken as seed to search the node j whose weight ratio (Wj/Wseed) was greater than a certain threshold. The value of the j node was considered, to repeat the search. A module was constituted until the threshold value was met. The searched nodes were removed from the network, so the searching number of each node was not >1. Next, the modules, which included >10 genes in the networks, were selected to perform the Gene Ontology enrichment analysis by DAVID.
Results

DEG analysis.
A total of 1151 genes between normal and astrocytoma tissues, 684 genes between normal and glioblastoma tissues, and 551 genes between normal and oligodendroglioma tissues were filtered as DEGs, respectively.
Function enrichment of DEGs. Following the GO enrichment analysis, it was identified that the functions of DEGs in the three types of glioma were significantly different. The DEGs in astrocytoma were mainly involved in neuron signal transmission processes, including the synapse, synapse part and synaptic transmission ( Table I ). The DEGs of the glioblastoma were mainly involved in the immune response and antigen processing (Table II) , and for oligodendroglioma, the DEGs were mainly involved in signal transmission processes, including GTPase activity and GTP binding (Table III) .
Co-expression networks of DEGs. Co-expression networks of the three types of glioma were constructed, and the genes with a Pearson's correlation coefficient >0.7 were selected as the co-expressed gene pairs. A total of 77232, 455 and 987 interactions were involved in the differentially co-expressed networks of astrocytoma (Fig. 1), oligodendroglioma (Fig. 2) and glioblastoma (Fig. 3) , respectively. From the three co-expression networks it was observed that they all had significantly different modularity, so their functions exhibited different emphases.
Function module mining and analysis. The MCODE method was used to mine the network modules. A total of 32, 7 and 10 modules were excavated from the differential co-expression networks of astrocytoma, glioblastoma and oligodendroglioma, respectively. The five modules with the maximum number of genes selected from the networks of the three types of glioma are demonstrated in Fig. 4 . The modules that included >10 genes in the networks of the three types of glioma were selected for GO enrichment analysis. The functions of the five modules of astrocytoma showed the diverse regulation of astrocytoma: Module1 was mainly involved in the function of neural signal transmission, including synaptic transmission, multicellular organismal signaling and transmission of nerve impulse. The functions of Module2 were mainly associated with the immune response, defense response and regulation of immune system processes. The functions of Module3 were mainly correlated with the myelin sheath. The functions of Module4 were mainly associated with the cell cycle and Module5 was mainly involved in signal transmission functions. Among them, the functions of Module1 and Module2 were summarized in Table IV . PAK3 p21-activated kinase 3 (PAK3) and docking protein 6 (DOK-6) were two genes in these modules.
Only two modules of the glioblastoma network contained >10 genes, and their enriched functions are demonstrated in Table V . Module1 was mainly enriched in functions related to immune response, regulation of immune responses and defense responses. Module2 was mainly enriched in biological processes, including cytoskeletal anchoring at plasma membrane, protein phosphorylation and regulation of sodium ion transport. CD86 and WNK lysine deficient protein kinase 2 (WNK2) were two genes in these modules.
Only one module was excavated with >10 genes in the differentially co-expressed network of oligodendroglioma, and it was identified that its functions were mainly enriched in the synthesis of organic acids. Cyclin-dependent kinase 5 (Cdk5) and DOK-6 were two genes in the module.
Discussion
Glioma is a multi-stage process, involving a variety of changes in gene expression and physiological structure, such as the Regulation of sodium ion transport (BP) 4.280E-2 expansion of suppressor cells, and is associated with high rates of patient mortality and morbidity (24) . Therefore, examining the mechanism of glioma development and developing an effective prevention strategy is urgently required. In the present study, based on the gene expression profiling, DEGs associated with the three types of glioma (astrocytoma, glioblastoma and oligodendroglioma) were screened and co-expression networks were constructed. Next, the function modules were mined to determine the functional connections and differences in the DEGs in the three types of glioma. Based on the enrichment analysis of DEGs and modules, it was identified that the functions of DEGs were consistent with the modules in the three types of glioma. Therefore, DEGs in astrocytoma were mainly correlated with synaptic signaling, while those in glioblastoma were most commonly associated with protein phosphorylation and sodium ion transportation. The DEGs in the tissues from the two types of glioma had marked similarity, which was manifested by their relevance to immune response function. Conversely, DEGs in oligodendroglioma tissues were observed to be significantly difference compared with the other two types of glioma, as they were mainly associated with synthesis of organic acids; therefore, different treatment strategies may be required to treat this type of glioma.
Tumors arise through a combination of tumor-promoting inflammation and a failure of spontaneous antitumor immunity. Tumors have also been shown to initiate due to alterations in immune response genes in the absence of germline mutations in known oncogenes or anti-oncogenes. In addition, antitumor immunity has been shown to limit tumor growth (25) . However, chronic immune activation also leads to the induction of immune-regulatory responses that promote tumorigenesis (25) . Cancers are highly difficult for the immune system to eliminate as it is difficult to distinguish between healthy and tumor tissues. Those that have already escaped natural immunosurveillance have bypassed the natural immune barriers to malignancy (26) . It may be concluded from the present study that the DEGs in astrocytoma and glioblastoma tissues were associated with the immune response. Therefore, understanding the molecular mechanisms (27) that separate tumor-promoting inflammation from antitumor immunity in tumor development may provide insights into inflammation-associated malignancies and contribute to the generation of immune therapies for cancer.
PAK3, which was involved in the co-expression network of the DEGs identified in astrocytoma tissues, has been previously demonstrated to be implicated in glioma invasion (28, 29) , and PAK is a potential therapeutic target in schwannomas (30) . DOK-6 expression was relatively high in several human neuroblastoma cell lines and detected in the developing neocortex, diencephalon, spinal cord and cranial parasympathetic nerve (31) , which suggests that it has functional roles in neuronal cells. Understanding signal transmission within neural cells is a crucial issue in neuroscience. Nervous system signaling disorders are known to cause numerous diseases, including Parkinson's disease, Alzheimer's disease and cancer (32) . DEGs identified in astrocytoma tissues were mainly associated with synaptic signaling, thus novel drugs may be identified that interfere with these pathways.
CD86, a co -stimulatory molecule, is downregulated in glioblastoma to evade immune recognition (33) . WNK2 acts as a recurrent target for epigenetic silencing in glia-derived brain tumors and is associated with tumor cell invasion and proliferation (34) . One study indicated that the loss of WNK2 expression may contribute to the highly invasive phenotype of glioblastomas and it is important for tumor cell survival and cell cycle progression (35) . Protein phosphorylation is involved in the majority of cellular processes and thousands of distinct phosphorylation events may be detected in a single cell type (36) . Enrichment analysis of the genes identified through the kinase-substrate network approach suggested that genes encoding phosphorylated signaling hubs are often disease-associated genes, and genes encoding conserved phosphoproteins are associated with cancer (37) . Phorbol esters are tumor promoters and mitogens, whose effects may be mediated by changes in ion transport across membranes. They activate the physiological amiloride-and cAMP-sensitive channels gating apical Na + entry from the mucosal medium into the epithelial cells, which is associated with tumor occurrence (38, 39) . DEGs in the glioblastoma tissues were mainly associated with protein phosphorylation and sodium ion transportation, thus further studies are required to determine whether the genes identified in this study may be targeted clinically in the treatment of glioma.
It has been demonstrated that Cdk5 (40) and DOK-6 (31) were upregulated in oligodendroglioma tissues and have roles in the occurrence of oligodendroglioma. Recent studies have demonstrated that organic acids are cytotoxic against numerous human tumor types, including neuroectodermal and malignant brain tumors (41, 42) . With regard to its anticancer properties, betulinic acid (a type of organic acid) was previously reported to exhibit selective cytotoxicity against several melanoma-derived cell lines (41) . Due to its selective cytotoxicity against tumor cells and favorable therapeutic index, betulinic acid is a highly promising novel chemotherapeutic agent for the treatment of cancer (43) . DEGs in oligodendroglioma tissue were mainly those associated with the synthesis of organic acids, and this analysis may aid in the development of novel treatment strategies for the disease.
Reasonable use of microarray gene expression profiling not only renders the analysis of large quantities of biological information quick and simple, but also facilitates the accurate identification of the key molecular mechanisms associated with glioma biological behavior. In the present study, it was demonstrated that distinct treatments should be administrated for the three types of glioma, due to their different functions analyzed from the mined network modules. Furthermore, the results of the present study implied that PAK3 and DOK-6, CD86 and WNK2, and Cdk5 may possibly be the target genes relevant to astrocytoma, glioblastoma and oligodendroglioma respectively. This may be useful in investigating the complex interacting mechanisms underlying the disease, and provides a novel strategy, which may aid with the development of novel therapies for the different types of glioma. However, further studies are required to confirm these results and determine their clinical utility.
